CCR Clinical Trials at NIH: Clinical Research: Search for Clinical Trials at NIH

The NCI Center for Cancer Research (CCR) conducts more than 150 cancer clinical trials at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. Cancer clinical trials that take place at the NIH Clinical Center are open to patients with cancer, regardless of where they live in the United States.

Go to Search Page

There are 16 clinical trials at NIH that match your search criteria

Cancer by type/disease: Prostate Cancer

Trial and Protocol Number Prostate Cancer	Principal Investigator	Referral Contact
Phase III
A Randomized, Double-Blind, Phase III Efficacy Trial of PROSTVAC-V/F Plus or Minus GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer NCI-11-C-0262, NCT01322490	James L. Gulley 301-435-2956	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
Phase II
NaF PET/CT Repeatability, Responsiveness, and Response Assessment in Patients With Metastatic Castrate-Resistant Prostate Cancer to Bone Treated With Either Docetaxel-Based Chemotherapy or Androgen Receptor (AR)-Directed Therapies NCI-12-C-0080, NCT01516866	Andrea B. Apolo 301-496-4916	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
A Phase II Study of AMG 386 and Abiraterone in Metastatic Castration Resistant Prostate Cancer NCI-12-C-0079, NCT01553188	William L. Dahut 301-435-8183	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
A Randomized Phase II Study of L-BLP25 in Combination With Standard Androgen Deprivation Therapy and Radiation Therapy for Newly Diagnosed, High Risk Prostate Cancer Patients NCI-11-C-0247, NCT01496131	Ravi A. Madan 301-496-3493	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
MR Image Guided Focal Therapy in Prostate Cancer NCI-11-C-0158, NCT01377753	Peter A. Pinto 301-496-6353	Celene Chua 301-402-4346 cchua@mail.nih.gov
Evaluation of Ferumoxytol Enhanced MRI for the Detection of Lymph Node Involvement in Prostate Cancer NCI-11-C-0098, NCT01296139	Peter Choyke 301-402-8409	Yolanda McKinney 301-443-6913 ymckinney@mail.nih.gov
A Phase II Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) NCI-09-C-0195, NCT00942578	William L. Dahut 301-435-8183	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
A Randomized Phase II Trial Combining Vaccine Therapy With PROSTVAC/TRICOM and Flutamide vs. Flutamide Alone in Men With Androgen Insensitive, Non-Metastatic (D0.5) Prostate Cancer NCI-07-C-0107, NCT00450463	Ravi A. Madan 301-496-3493	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
Phase I/II
A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer NCI-10-C-0062, NCT01090765	William L. Dahut 301-435-8183	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
Phase I
A Phase I Study of Cabozantinib (XL184) Plus Docetaxel and Prednisone in Metastatic Castrate Resistant Prostate Cancer NCI-12-C-0204 , NCT01683994	William L. Dahut 301-435-8183	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov

Trial and Protocol Number Solid Tumor	Principal Investigator	Referral Contact
Phase II
Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 TCR-Gene Engineered Lymphocytes NCI-08-C-0121, NCT00670748	Steven A. Rosenberg 1-866-820-4505 (Toll Free)	June A. Kryk 1-866-820-4505 (Toll Free) ncisbirc@mail.nih.gov
Phase I
A Phase I, Open-label, Multiple-Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C, a Monoclonal Anti-PD-L1 Antibody, in Adults With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications NCI-13-C-0063, NCT01772004	James L. Gulley 301-435-2956	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
A Phase I Study of an Adenoviral Transduced Autologous Dendritic Cell Vaccine Expressing Human HER2/neu ECTM in Adults With Tumors With 1-3+ HER2/neu Expression NCI-13-C-0016, NCT01730118	Lauren V. Wood 301-402-0199	Brenda Roberson 301-435-4733 broberson@mail.nih.gov
An Open Label Phase I Study to Evaluate the Safety and Tolerability of GI-6301 Vaccine Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express Brachyury Protein in Adults With Solid Tumors NCI-12-C-0056, NCT01519817	James L. Gulley 301-435-2956	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
Phase I Trial of Z-Endoxifen in Adults With Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or other Hormone Receptor-Positive Solid Tumors NCI-11-C-0061, NCT01273168	Shivaani Kummar 301-435-0517	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
No Phase
A Natural History Study of Patients Receiving High Dose Rate Brachytherapy NCI-09-C-0100, NCT00924027	Aradhana Kaushal 301-496-5457	Sharon L. Smith 301-496-5457 smiths@mail.nih.gov

For additional studies that may be appropriate for your disease type, please search under Solid Tumor.